Study Unlocks AI Use in the Identification of New Genetic Factor Responsible for Prostate Cancer Progression.
In a study published in Digital Medicine, it was reported that Artificial intelligence (AI) helps in the detection of changes in a gene called ZNF268, which stimulates the progression of prostate cancers despite an initially reassuring risk assessment. Similarly, the application of machine learning supports predicting cancer progression and identifying important genetic changes. Compared to the standard assessments, which use information such as prostate-specific antigen (PSA) levels, biopsy results, and tumour stage, which may not capture every biological change that makes cancer more dangerous, AI offers a wide range of applications.
The study also highlighted the use of machine learning methods combining different types of biological data, including genetic changes and gene activity. This also helps in the identification of cases missed by standard risk assessments. This, in turn, helps in enhancing the risk prediction of prostate cancer and supports the development of more personalized treatment in the future.
Furthermore, ZNF268, a gene linked to how prostate cancer behaves, was identified by the researchers in the study conducted in 498 prostate cancer cases, and they checked their findings against other patient groups. Thus, it was noted that the lower its activity, the more aggressive the disease, even among patients classified as having low- or intermediate-risk cancer. The researcher also developed a score linked to cancer progression, identifying how genes work together and patients who need closer monitoring.
Moreover, a study published in Frontiers in Oncology examined 410 patients with hormone-sensitive prostate cancer, which utilized several machine learning models in order to predict which patients might develop more advanced disease. More promising results were observed by Random Forest and XGBoost models, which indicated that progression risk can be estimated by clinical details and test results.
Urologic Oncology: Seminars and Original Investigations offered another review, which outlined research on AI and genetic markers in prostate cancer. This study identified that AI can support the detection of cancer-related genes, estimate how tumours might respond to treatment, and predict disease outcomes. It also reported that despite these applications of AI, more clinical validation is required before these methods can be widely used.
Thus, it can be concluded that these findings indicate that AI could help doctors look beyond routine test results and better understand which cancers may need closer attention. Additionally, despite their promising results from research models, these tools are required to undergo clinical validation before their use for routine patient care.
Based on the study published in npj Digital Medicine, the ZNF268 gene may help distinguish some less aggressive-looking tumours from tumours showing more dangerous behaviour. It was highlighted that lower ZNF268 activity was linked to changes in how tumour cells use energy and regulate other important biological processes, signalling movement of cancer towards a more aggressive state.
Additionally, possible weaknesses in these tumours were also identified by the research, which could help in the development of new treatments. However, these potential treatment targets were detected with biological and computer-based analyses and may lack evidence to support the development of drugs targeting this gene pattern.
Thus, this study supports doctors in understanding why two patients with similar routine test results can have different outcomes. Additionally, it also offers insights into biomarkers that provide additional information about the likely behaviour of a tumour.
AI helps in identifying patients requiring earlier treatment, closer follow-up, identify new biomarkers and potential treatment targets. It also helps in identifying hidden signs of aggressive disease earlier. They are also anticipated to support more accurate risk assessment and more personalised care for people with prostate cancer.
However, these tools are not yet ready to replace standard medical assessments, as doctors continue to rely on established clinical information, including PSA levels, biopsy findings, tumour stage, and other relevant factors, when assessing prostate cancer.
Expanding AI applications across the healthcare sector is offering a diagnostic application for prostate cancer. Despite the use of standard medical assessment, AI is used for the identification of genetic factors responsible for the progression of the cancer, as well as detection of new tumor weaknesses, and insights for new treatment development are also offered by AI. It also promotes diagnostic efficiency and interpretation of complex medical data. This, in turn, is anticipated to drive the adoption of AI tools for individualized cancer assessment and personalized treatment development.
Link to this news: AI Finds a Potential Genetic Clue to Prostate Cancer Progression
